NYSE: ABBVAbbvie Inc Stock
$193.51+1.17 (+0.61%)
Updated Apr 29, 2025
ABBV Price
$193.51
Fair Value Price
N/A
Market Cap
$341.61B
52 Week Low
$153.58
52 Week High
$218.66
P/E
80.63x
P/B
102.74x
P/S
5.58x
PEG
0.93x
Dividend Yield
2.45%
Revenue
$56.33B
Earnings
$4.28B
Gross Margin
70%
Operating Margin
10.42%
Profit Margin
7.6%
Debt to Equity
39.64
Operating Cash Flow
$19B
Beta
0.38
Next Earnings
N/A
Ex-Dividend
Apr 15, 2025
Next Dividend
May 15, 2025
ABBV Overview
AbbVie Inc. is a research focused biopharmaceutical company. The company produces pharmaceutical drugs for immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, virology, and other serious health conditions. The company was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABBV's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
ABBV
Ranked#8 of 18
Ranked#8 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $113.45 | A | |
| $71.71 | A | |
| $155.91 | A |
Be the first to know about important ABBV news, forecast changes, insider trades & much more!
ABBV News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABBV scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABBV ($193.51) is trading above its intrinsic value of $87.69, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABBV is poor value based on its earnings relative to its share price (80.63x), compared to the US market average (29.19x)
P/E vs Market Valuation
ABBV is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ABBV due diligence checks available for Premium users.
Valuation
ABBV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
80.63x
Industry
54.14x
Market
29.19x
ABBV is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABBV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABBV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
102.74x
Industry
6.28x
ABBV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABBV price to earnings growth (PEG)
For valuing profitable companies with growth potential
ABBV is good value based... subscribe to Premium to read more.
PEG Value Valuation
ABBV's financial health
Profit margin
Revenue
$15.1B
Net Income
-$22.0M
Profit Margin
-0.1%
ABBV's Earnings (EBIT) of $5.87B... subscribe to Premium to read more.
Interest Coverage Financials
ABBV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$135.2B
Liabilities
$131.8B
Debt to equity
39.64
ABBV's short-term liabilities ($38.75B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABBV's long-term liabilities ($93.05B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABBV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABBV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.0B
Investing
-$1.9B
Financing
-$6.9B
ABBV's operating cash flow ($18.81B)... subscribe to Premium to read more.
Debt Coverage Financials
ABBV vs General Drug Manufacturer Stocks
Abbvie Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.